America First Investment Advisors LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,330 shares of the healthcare product maker’s stock after acquiring an additional 6,458 shares during the quarter. Abbott Laboratories makes up approximately 4.6% of America First Investment Advisors LLC’s holdings, making the stock its 12th largest holding. America First Investment Advisors LLC’s holdings in Abbott Laboratories were worth $12,217,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Janney Capital Management LLC lifted its holdings in Abbott Laboratories by 0.4% during the 1st quarter. Janney Capital Management LLC now owns 6,229 shares of the healthcare product maker’s stock worth $276,000 after buying an additional 26 shares in the last quarter. Delta Asset Management LLC TN lifted its holdings in Abbott Laboratories by 1.3% during the 1st quarter. Delta Asset Management LLC TN now owns 3,996 shares of the healthcare product maker’s stock worth $178,000 after buying an additional 51 shares in the last quarter. Farmers National Bank lifted its holdings in Abbott Laboratories by 1.5% during the 1st quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock worth $158,000 after buying an additional 52 shares in the last quarter. Alexandria Capital LLC lifted its holdings in Abbott Laboratories by 0.5% during the 1st quarter. Alexandria Capital LLC now owns 11,318 shares of the healthcare product maker’s stock worth $503,000 after buying an additional 56 shares in the last quarter. Finally, iAB Financial Bank lifted its holdings in Abbott Laboratories by 0.4% during the 1st quarter. iAB Financial Bank now owns 27,050 shares of the healthcare product maker’s stock worth $1,201,000 after buying an additional 100 shares in the last quarter. 71.50% of the stock is currently owned by institutional investors and hedge funds.

ABT has been the topic of several research reports. BidaskClub raised Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a report on Thursday, June 29th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Friday, May 26th. Stifel Nicolaus upped their price objective on Abbott Laboratories from $49.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, May 31st. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 price objective (up previously from $47.50) on shares of Abbott Laboratories in a report on Friday, June 30th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Abbott Laboratories currently has an average rating of “Buy” and a consensus target price of $52.50.

In other Abbott Laboratories news, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the sale, the insider now directly owns 143,154 shares of the company’s stock, valued at $7,157,700. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at $10,963,656. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 218,150 shares of company stock valued at $10,811,179. Insiders own 0.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Abbott Laboratories (ABT) Stake Lifted by America First Investment Advisors LLC” was published by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/abbott-laboratories-abt-stake-lifted-by-america-first-investment-advisors-llc/1576188.html.

Abbott Laboratories (NYSE:ABT) traded up 0.56% during mid-day trading on Wednesday, hitting $51.70. 1,829,793 shares of the company were exchanged. The company’s 50-day moving average is $50.14 and its 200 day moving average is $47.04. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $52.60. The company has a market capitalization of $89.83 billion, a P/E ratio of 72.41 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. The business had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories’s revenue for the quarter was up 24.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 earnings per share. Analysts expect that Abbott Laboratories will post $2.49 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be paid a $0.265 dividend. This represents a $1.06 annualized dividend and a yield of 2.06%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 149.30%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.